MDS 2023 | Efficacy and safety of safinamide in PD patients across different age groups

Andreia Ferreira, MD, Braga Hospital, Braga, Portugal, discusses the efficacy and safety of safinamide, an inhibitor of type-B monoamine oxidase (MAO-B), in the treatment of Parkinson’s disease (PD) across different age groups. The study aimed to compare the outcomes in patients under 70 years old versus those over 70 years old. The results revealed statistically significant differences in both motor and non-motor variables, particularly at one year of treatment, including improvements in bradykinesia, morning kinesia, and wearing off. Surprisingly, age did not significantly impact the efficacy of safinamide. The study also identified important predictors of non-responsiveness to safinamide treatment, such as postural stability and cognitive impairment. These findings suggest the potential reconsideration of current prescribing guidelines for safinamide in older patients. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.